Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract

N/ANot Yet RecruitingNCT06939907

Next Biomedical Co., Ltd.60 enrolled

Overview

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lower Gastrointestinal Bleeding Diverticular Bleeding

Interventions

Nexpowder™DEVICE

Nexpowder™ hemostatic powder

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults aged 19 years or older at the time of screening * Patients diagnosed with diverticular bleeding Exclusion Criteria: * Patients diagnosed with upper gastrointestinal bleeding

Locations (6)

Chungbuk National University Hospital

Cheongju-si, South Korea

Chungnam National University Hospital

Daejeon, South Korea

Chosun University Hospital

Gwangju, South Korea

Sejong Chungnam National University Hospital

Sejong, South Korea

Outcomes

Primary Outcomes

Rebleeding rate

30 days after successful endoscopic hemostasis

Time frame: 30 days post treatment

Secondary Outcomes

Hemostasis rate

Time frame: Immediately after the procedure

Rebleeding rate

Time frame: 7 days post treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.